Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.

Atkinson JM, Falconer RA, Edwards DR, Pennington CJ, Siller CS, Shnyder SD, Bibby MC, Patterson LH, Loadman PM, Gill JH.

Cancer Res. 2010 Sep 1;70(17):6902-12. doi: 10.1158/0008-5472.CAN-10-1440. Epub 2010 Jul 27.

PMID:
20663911
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Tumor-targeted prodrug ICT2588 demonstrates therapeutic activity against solid tumors and reduced potential for cardiovascular toxicity.

Gill JH, Loadman PM, Shnyder SD, Cooper P, Atkinson JM, Ribeiro Morais G, Patterson LH, Falconer RA.

Mol Pharm. 2014 Apr 7;11(4):1294-300. doi: 10.1021/mp400760b. Epub 2014 Mar 27.

PMID:
24641451
[PubMed - in process]
3.

A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line.

Shinoda K, Shibuya M, Hibino S, Ono Y, Matsuda K, Takemura A, Zou D, Kokubo Y, Takechi A, Kudoh S.

Int J Oncol. 2003 Feb;22(2):281-8.

PMID:
12527923
[PubMed - indexed for MEDLINE]
4.

Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity.

Albright CF, Graciani N, Han W, Yue E, Stein R, Lai Z, Diamond M, Dowling R, Grimminger L, Zhang SY, Behrens D, Musselman A, Bruckner R, Zhang M, Jiang X, Hu D, Higley A, Dimeo S, Rafalski M, Mandlekar S, Car B, Yeleswaram S, Stern A, Copeland RA, Combs A, Seitz SP, Trainor GL, Taub R, Huang P, Oliff A.

Mol Cancer Ther. 2005 May;4(5):751-60.

PMID:
15897239
[PubMed - indexed for MEDLINE]
Free Article
5.

Competitive disruption of the tumor-promoting function of membrane type 1 matrix metalloproteinase/matrix metalloproteinase-14 in vivo.

Nonaka T, Nishibashi K, Itoh Y, Yana I, Seiki M.

Mol Cancer Ther. 2005 Aug;4(8):1157-66.

PMID:
16093431
[PubMed - indexed for MEDLINE]
Free Article
6.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

PMID:
14522925
[PubMed - indexed for MEDLINE]
Free Article
7.

Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis.

Deryugina EI, Soroceanu L, Strongin AY.

Cancer Res. 2002 Jan 15;62(2):580-8.

PMID:
11809713
[PubMed - indexed for MEDLINE]
Free Article
8.

The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.

Foley KP, Zhou D, Borella C, Wu Y, Zhang M, Jiang J, Li H, Sang J, Korbut T, Ye J, Zhang X, Barsoum J, Sonderfan AJ.

J Pharmacol Exp Ther. 2012 Nov;343(2):529-38. doi: 10.1124/jpet.112.196873. Epub 2012 Jul 26.

PMID:
22837008
[PubMed - indexed for MEDLINE]
Free Article
9.

ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.

Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA.

Cancer Res. 2002 Dec 15;62(24):7247-53.

PMID:
12499266
[PubMed - indexed for MEDLINE]
Free Article
10.

Characterization of matrix metalloproteinase inhibitors: angiogenesis and tumor models.

Albert DH, Davidsen SK.

Curr Protoc Pharmacol. 2001 Aug;Chapter 5:Unit5.23. doi: 10.1002/0471141755.ph0523s13.

PMID:
21959760
[PubMed - indexed for MEDLINE]
11.

Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.

Maquoi E, Sounni NE, Devy L, Olivier F, Frankenne F, Krell HW, Grams F, Foidart JM, Noël A.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4038-47.

PMID:
15217936
[PubMed - indexed for MEDLINE]
Free Article
12.

CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.

Dubois V, Dasnois L, Lebtahi K, Collot F, Heylen N, Havaux N, Fernandez AM, Lobl TJ, Oliyai C, Nieder M, Shochat D, Yarranton GT, Trouet A.

Cancer Res. 2002 Apr 15;62(8):2327-31.

PMID:
11956091
[PubMed - indexed for MEDLINE]
Free Article
13.

Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase.

Kondo M, Asai T, Katanasaka Y, Sadzuka Y, Tsukada H, Ogino K, Taki T, Baba K, Oku N.

Int J Cancer. 2004 Jan 10;108(2):301-6.

PMID:
14639619
[PubMed - indexed for MEDLINE]
14.

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.

Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL.

Cancer Res. 2008 Jan 1;68(1):206-15. doi: 10.1158/0008-5472.CAN-07-0669. Erratum in: Cancer Res. 2008 Jul 15;68(1):6030.

PMID:
18172313
[PubMed - indexed for MEDLINE]
Free Article
15.

Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.

Liu S, Wang H, Currie BM, Molinolo A, Leung HJ, Moayeri M, Basile JR, Alfano RW, Gutkind JS, Frankel AE, Bugge TH, Leppla SH.

J Biol Chem. 2008 Jan 4;283(1):529-40. Epub 2007 Nov 1.

PMID:
17974567
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.

Alfano RW, Leppla SH, Liu S, Bugge TH, Ortiz JM, Lairmore TC, Duesbery NS, Mitchell IC, Nwariaku F, Frankel AE.

Mol Cancer Ther. 2010 Jan;9(1):190-201. doi: 10.1158/1535-7163.MCT-09-0694. Epub 2010 Jan 6.

PMID:
20053778
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin.

Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH.

Cancer Res. 2000 Nov 1;60(21):6061-7.

PMID:
11085528
[PubMed - indexed for MEDLINE]
Free Article
18.

Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.

Devy L, de Groot FM, Blacher S, Hajitou A, Beusker PH, Scheeren HW, Foidart JM, Noël A.

FASEB J. 2004 Mar;18(3):565-7. Epub 2004 Jan 20.

PMID:
14734647
[PubMed - indexed for MEDLINE]
Free Article
19.

Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.

Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK.

Mol Cancer Ther. 2009 Jun;8(6):1596-605. doi: 10.1158/1535-7163.MCT-08-1004. Epub 2009 Jun 9.

PMID:
19509267
[PubMed - indexed for MEDLINE]
Free Article
20.

A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy.

Crielaard BJ, van der Wal S, Lammers T, Le HT, Hennink WE, Schiffelers RM, Storm G, Fens MH.

Int J Nanomedicine. 2011;6:2697-703. doi: 10.2147/IJN.S24450. Epub 2011 Nov 2.

PMID:
22114500
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk